Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

NEXT STORY
Global Point-of-Care Imaging Devices Market: Focus on Product Type, Technology Type, Clinical Utility, Application, End User, 23 Countries’ Data, COVID-19 Impact, and Competitive Landscape – Analysis and Forecast, 2020-2030
PREV STORY
Fortress Biotech Announces $60 Million Loan Agreement with Oaktree Capital Management
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in Psoriatic Arthritis

Martinsried / Munich, Germany, Nov. 15, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; ...

author_avatar
NASDAQ Market News

Point-of-Care Molecular Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product & Services, Technology [PCR, Isothermal Nucleic Acid Amplification Technology, and Other Technologies], Application, and End User Geography

author_avatar
NASDAQ Market News

IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

author_avatar
NASDAQ Market News